Loading
DB-1305 / BNT325 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.
SABCS 2025 abstract PS5-02-29 reports 26 previously treated metastatic TNBC patients at the March 31, 2025 cutoff. Prior sacituzumab govitecan was excluded. Median follow-up was 9.3 months; grade 3 or higher treatment-related adverse events occurred in 9/26 patients (34.6%) and one discontinued for anemia. The deposited abstract does not provide its referenced efficacy table, so a response rate is not inferred. This uncontrolled cohort cannot rank DB-1305 against approved ADCs.
TROP2-directed antibody-drug conjugate with a cleavable linker and a topoisomerase I inhibitor. Connects to TROP2.
1.DB-1305 / BNT325's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DB-1305 / BNT325" OR ABSTRACT:"DB-1305 / BNT325") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DB-1305 / BNT325, not a curated reading list.
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Shares TROP2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/